These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10613450)

  • 1. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
    Giles FJ; O'Brien SM; Santini V; Gandhi V; Plunkett W; Seymour JF; Robertson LE; Kantarjian HM; Keating MJ
    Leuk Lymphoma; 1999 Dec; 36(1-2):57-65. PubMed ID: 10613450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
    Tsimberidou AM; O'Brien SM; Cortes JE; Faderl S; Andreeff M; Kantarjian HM; Keating MJ; Giles FJ
    Leuk Lymphoma; 2002 Apr; 43(4):767-72. PubMed ID: 12153163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V; Robertson LE; Keating MJ; Plunkett W
    Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
    Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
    O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M
    Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
    Tsimberidou AM; Wierda WG; Wen S; Plunkett W; O'Brien S; Kipps TJ; Jones JA; Badoux X; Kantarjian H; Keating MJ;
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):568-74. PubMed ID: 23810245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
    Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
    Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
    Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
    Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Keating MJ
    Leukemia; 1995 Jun; 9(6):943-5. PubMed ID: 7596181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
    Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
    Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Jain N; Balakrishnan K; Ferrajoli A; O'Brien SM; Burger JA; Kadia TM; Cortes JE; Ayres ML; Tambaro FP; Keating MJ; Gandhi V; Wierda WG
    Oncotarget; 2017 Mar; 8(13):22104-22112. PubMed ID: 27655665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.